A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma

Trial Profile

A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Ceritinib (Primary)
  • Indications Anaplastic large cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Jun 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Feb 2023.
    • 16 Jun 2017 Planned initiation date changed from 1 Jun 2017 to 1 Aug 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top